WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia

Zsófia Ujj, Gergely Buglyó, M. Udvardy, György Vargha, Sándor Biró, László Rejto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The Wilms tumor 1 (WT1) gene has a complex role as a transcriptional regulator, acting as tumor suppressor or oncogene in different malignancies. The prognostic role of its overexpression has been well-studied in leukemias, especially acute myeloid leukemia (AML), but not in lymphomas. For the first time to our knowledge, we present a study demonstrating the correlation of WT1 expression and survival in various non-Hodgkin lymphomas. We also studied the prognostic implications of WT1 overexpression in adult acute lymphoblastic leukemia (ALL). In our sample of 53 patients-25 with diffuse large B-cell lymphoma (DLBCL), 8 with mantle cell lymphoma (MCL), 9 with peripheral T-cell lymphoma (PTCL), 2 with Burkitt's lymphoma, 2 with mucosa-associated lymphoid tissue (MALT) lymphoma, and 7 with B-cell ALL-, we measured WT1 mRNA from blood samples by quantitative RT-PCR, and divided the patients into subgroups based on the level of expression. Kaplan-Meier survival curves were drawn and compared using the logrank test. In the sample of DLBCL patients, the difference in overall and disease-free survival between WT1-positive and negative subgroups was significant (p = 0.0475 and p = 0.0004, respectively), and in a few observed cases, a sudden increase in WT1 expression signified a relapse soon followed by death. Disease-free survival curves in MCL and ALL were similarly suggestive of a potential role played by WT1. In PTCL, though WT1-positivity was detected in 4 out of 9 cases, it did not seem to affect survival. The few cases of MALT and Burkitt's lymphoma all proved to be WT1-negative.

Original languageEnglish
Pages (from-to)565-570
Number of pages6
JournalPathology and Oncology Research
Volume20
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Wilms Tumor
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Peripheral T-Cell Lymphoma
Mantle-Cell Lymphoma
Marginal Zone B-Cell Lymphoma
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival
Wilms' Tumor Genes
Survival
Kaplan-Meier Estimate
Oncogenes
Acute Myeloid Leukemia
Lymphoma
Neoplasms
Leukemia
B-Lymphocytes
Recurrence
Polymerase Chain Reaction

Keywords

  • Acute lymphoblastic leukemia
  • Diffuse large B-cell lymphoma
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Overexpression
  • WT1 gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia. / Ujj, Zsófia; Buglyó, Gergely; Udvardy, M.; Vargha, György; Biró, Sándor; Rejto, László.

In: Pathology and Oncology Research, Vol. 20, No. 3, 2014, p. 565-570.

Research output: Contribution to journalArticle

Ujj, Zsófia ; Buglyó, Gergely ; Udvardy, M. ; Vargha, György ; Biró, Sándor ; Rejto, László. / WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia. In: Pathology and Oncology Research. 2014 ; Vol. 20, No. 3. pp. 565-570.
@article{f8e2005242a24c0680441fcf8cf03ddc,
title = "WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia",
abstract = "The Wilms tumor 1 (WT1) gene has a complex role as a transcriptional regulator, acting as tumor suppressor or oncogene in different malignancies. The prognostic role of its overexpression has been well-studied in leukemias, especially acute myeloid leukemia (AML), but not in lymphomas. For the first time to our knowledge, we present a study demonstrating the correlation of WT1 expression and survival in various non-Hodgkin lymphomas. We also studied the prognostic implications of WT1 overexpression in adult acute lymphoblastic leukemia (ALL). In our sample of 53 patients-25 with diffuse large B-cell lymphoma (DLBCL), 8 with mantle cell lymphoma (MCL), 9 with peripheral T-cell lymphoma (PTCL), 2 with Burkitt's lymphoma, 2 with mucosa-associated lymphoid tissue (MALT) lymphoma, and 7 with B-cell ALL-, we measured WT1 mRNA from blood samples by quantitative RT-PCR, and divided the patients into subgroups based on the level of expression. Kaplan-Meier survival curves were drawn and compared using the logrank test. In the sample of DLBCL patients, the difference in overall and disease-free survival between WT1-positive and negative subgroups was significant (p = 0.0475 and p = 0.0004, respectively), and in a few observed cases, a sudden increase in WT1 expression signified a relapse soon followed by death. Disease-free survival curves in MCL and ALL were similarly suggestive of a potential role played by WT1. In PTCL, though WT1-positivity was detected in 4 out of 9 cases, it did not seem to affect survival. The few cases of MALT and Burkitt's lymphoma all proved to be WT1-negative.",
keywords = "Acute lymphoblastic leukemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma, Overexpression, WT1 gene",
author = "Zs{\'o}fia Ujj and Gergely Bugly{\'o} and M. Udvardy and Gy{\"o}rgy Vargha and S{\'a}ndor Bir{\'o} and L{\'a}szl{\'o} Rejto",
year = "2014",
doi = "10.1007/s12253-013-9729-7",
language = "English",
volume = "20",
pages = "565--570",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - WT1 overexpression affecting clinical outcome in non-Hodgkin lymphomas and adult acute lymphoblastic leukemia

AU - Ujj, Zsófia

AU - Buglyó, Gergely

AU - Udvardy, M.

AU - Vargha, György

AU - Biró, Sándor

AU - Rejto, László

PY - 2014

Y1 - 2014

N2 - The Wilms tumor 1 (WT1) gene has a complex role as a transcriptional regulator, acting as tumor suppressor or oncogene in different malignancies. The prognostic role of its overexpression has been well-studied in leukemias, especially acute myeloid leukemia (AML), but not in lymphomas. For the first time to our knowledge, we present a study demonstrating the correlation of WT1 expression and survival in various non-Hodgkin lymphomas. We also studied the prognostic implications of WT1 overexpression in adult acute lymphoblastic leukemia (ALL). In our sample of 53 patients-25 with diffuse large B-cell lymphoma (DLBCL), 8 with mantle cell lymphoma (MCL), 9 with peripheral T-cell lymphoma (PTCL), 2 with Burkitt's lymphoma, 2 with mucosa-associated lymphoid tissue (MALT) lymphoma, and 7 with B-cell ALL-, we measured WT1 mRNA from blood samples by quantitative RT-PCR, and divided the patients into subgroups based on the level of expression. Kaplan-Meier survival curves were drawn and compared using the logrank test. In the sample of DLBCL patients, the difference in overall and disease-free survival between WT1-positive and negative subgroups was significant (p = 0.0475 and p = 0.0004, respectively), and in a few observed cases, a sudden increase in WT1 expression signified a relapse soon followed by death. Disease-free survival curves in MCL and ALL were similarly suggestive of a potential role played by WT1. In PTCL, though WT1-positivity was detected in 4 out of 9 cases, it did not seem to affect survival. The few cases of MALT and Burkitt's lymphoma all proved to be WT1-negative.

AB - The Wilms tumor 1 (WT1) gene has a complex role as a transcriptional regulator, acting as tumor suppressor or oncogene in different malignancies. The prognostic role of its overexpression has been well-studied in leukemias, especially acute myeloid leukemia (AML), but not in lymphomas. For the first time to our knowledge, we present a study demonstrating the correlation of WT1 expression and survival in various non-Hodgkin lymphomas. We also studied the prognostic implications of WT1 overexpression in adult acute lymphoblastic leukemia (ALL). In our sample of 53 patients-25 with diffuse large B-cell lymphoma (DLBCL), 8 with mantle cell lymphoma (MCL), 9 with peripheral T-cell lymphoma (PTCL), 2 with Burkitt's lymphoma, 2 with mucosa-associated lymphoid tissue (MALT) lymphoma, and 7 with B-cell ALL-, we measured WT1 mRNA from blood samples by quantitative RT-PCR, and divided the patients into subgroups based on the level of expression. Kaplan-Meier survival curves were drawn and compared using the logrank test. In the sample of DLBCL patients, the difference in overall and disease-free survival between WT1-positive and negative subgroups was significant (p = 0.0475 and p = 0.0004, respectively), and in a few observed cases, a sudden increase in WT1 expression signified a relapse soon followed by death. Disease-free survival curves in MCL and ALL were similarly suggestive of a potential role played by WT1. In PTCL, though WT1-positivity was detected in 4 out of 9 cases, it did not seem to affect survival. The few cases of MALT and Burkitt's lymphoma all proved to be WT1-negative.

KW - Acute lymphoblastic leukemia

KW - Diffuse large B-cell lymphoma

KW - Mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - Overexpression

KW - WT1 gene

UR - http://www.scopus.com/inward/record.url?scp=84904105638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904105638&partnerID=8YFLogxK

U2 - 10.1007/s12253-013-9729-7

DO - 10.1007/s12253-013-9729-7

M3 - Article

C2 - 24374862

AN - SCOPUS:84904105638

VL - 20

SP - 565

EP - 570

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -